(ELVN) Enliven Therapeutics - Overview
Stock: Kinase Inhibitor, HER2 Inhibitor, Leukemia, Lung Cancer, Solid Tumors
| Risk 5d forecast | |
|---|---|
| Volatility | 66.1% |
| Relative Tail Risk | -8.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 11.97 |
| Character TTM | |
|---|---|
| Beta | 1.148 |
| Beta Downside | 1.273 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.93% |
| CAGR/Max DD | 0.20 |
Description: ELVN Enliven Therapeutics January 20, 2026
Enliven Therapeutics (NASDAQ: ELVN) is a clinical-stage biotech headquartered in Boulder, Colorado, developing small-molecule kinase inhibitors for oncology. Its lead pipeline includes ELVN-001, a BCR-ABL inhibitor currently in a Phase 1 trial for chronic myeloid leukemia (CML), and ELVN-002, an irreversible HER2 inhibitor with CNS penetration being evaluated in Phase 1 for HER2-driven non-small cell lung cancer (NSCLC) and other solid tumors.
As of the latest 10-Q (Q3 2024), the company reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month runway at current burn rates (~$3.5 million per quarter). The Phase 1 CML trial has enrolled 12 patients to date, and the HER2 trial has opened sites in the U.S. and Europe with a target enrollment of 30 patients in the first year.
Key sector dynamics that could influence ELVN’s upside include: (1) the growing market for oral kinase inhibitors, projected to exceed $30 billion by 2028; (2) FDA’s recent willingness to grant accelerated approvals for oncology drugs that demonstrate early efficacy signals; and (3) a modest but steady flow of venture capital into early-stage biotechs, with Q4 2024 biotech fundraising up ~8% YoY, supporting potential follow-on financing if needed.
For a deeper quantitative assessment, you may find ValueRay’s ELVN valuation model worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -97.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 7.81 > 1.0 |
| NWC/Revenue: 148.1k% < 20% (prev 63.6k%; Δ 84.5k% < -1%) |
| CFO/TA -0.15 > 3% & CFO -71.7m > Net Income -97.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 32.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.1m) vs 12m ago 28.65% < -2% |
| Gross Margin: 0.95% > 18% (prev 0.28%; Δ 66.53% > 0.5%) |
| Asset Turnover: 0.08% > 50% (prev 0.14%; Δ -0.06% > 0%) |
| Interest Coverage Ratio: -10.61 > 6 (EBITDA TTM -107.0m / Interest Expense TTM -10.1m) |
Altman Z'' -15.00
| A: 0.95 (Total Current Assets 482.7m - Total Current Liabilities 14.7m) / Total Assets 490.9m |
| B: -0.65 (Retained Earnings -317.5m / Total Assets 490.9m) |
| C: -0.27 (EBIT TTM -107.3m / Avg Total Assets 398.2m) |
| D: -21.50 (Book Value of Equity -317.2m / Total Liabilities 14.8m) |
| Altman-Z'' Score: -20.24 = D |
What is the price of ELVN shares?
Over the past week, the price has changed by +11.23%, over one month by +94.32%, over three months by +60.77% and over the past year by +30.93%.
Is ELVN a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.4 | 40.7% |
| Analysts Target Price | 41.4 | 40.7% |
| ValueRay Target Price | 30.3 | 2.9% |
ELVN Fundamental Data Overview February 03, 2026
Revenue TTM = 316.0k USD
EBIT TTM = -107.3m USD
EBITDA TTM = -107.0m USD
Long Term Debt = 387.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 387.0k USD (from shortTermDebt, last quarter)
Debt = 387.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -101.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (1.57b + Debt 387.0k - CCE 477.6m)
Interest Coverage Ratio = -10.61 (Ebit TTM -107.3m / Interest Expense TTM -10.1m)
EV/FCF = -15.21x (Enterprise Value 1.09b / FCF TTM -71.8m)
FCF Yield = -6.57% (FCF TTM -71.8m / Enterprise Value 1.09b)
FCF Margin = -22.7k% (FCF TTM -71.8m / Revenue TTM 316.0k)
Net Margin = -30.8k% (Net Income TTM -97.2m / Revenue TTM 316.0k)
Gross Margin = 0.95% ((Revenue TTM 316.0k - Cost of Revenue TTM 313.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.23 (Enterprise Value 1.09b / Total Assets 490.9m)
Interest Expense / Debt = 437.7% (Interest Expense 1.69m / Debt 387.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.8m (EBIT -107.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 32.95 (Total Current Assets 482.7m / Total Current Liabilities 14.7m)
Debt / Equity = 0.00 (Debt 387.0k / totalStockholderEquity, last quarter 476.1m)
Debt / EBITDA = 0.95 (negative EBITDA) (Net Debt -101.3m / EBITDA -107.0m)
Debt / FCF = 1.41 (negative FCF - burning cash) (Net Debt -101.3m / FCF TTM -71.8m)
Total Stockholder Equity = 390.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.41% (Net Income -97.2m / Total Assets 490.9m)
RoE = -24.88% (Net Income TTM -97.2m / Total Stockholder Equity 390.7m)
RoCE = -27.44% (EBIT -107.3m / Capital Employed (Equity 390.7m + L.T.Debt 387.0k))
RoIC = -21.70% (negative operating profit) (NOPAT -84.8m / Invested Capital 390.7m)
WACC = 10.14% (E(1.57b)/V(1.57b) * Re(10.14%) + (debt cost/tax rate unavailable))
Discount Rate = 10.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.87%
Fair Price DCF = unknown (Cash Flow -71.8m)
EPS Correlation: 33.75 | EPS CAGR: 177.3% | SUE: 4.0 | # QB: 3
Revenue Correlation: 17.67 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.42 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.98 | Chg30d=+0.000 | Revisions Net=+4 | Growth EPS=-14.9% | Growth Revenue=+0.0%